Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 16/20 | 0.56 |
| ▸ | CYSLTR1 | Q9Y271 | 16/20 | 0.56 |
| ▸ | BID | P55957 | 2/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9559832 | 0.88 | CYSLTR2 (0.50) | CYSLTR2CYSLTR1 | |
| SCHEMBL9158808 | 0.84 | CYSLTR2 (0.77) | CYSLTR2CYSLTR1 | |
| SCHEMBL9864623 | 0.84 | CYSLTR2 (0.77) | CYSLTR2CYSLTR1 | |
| SCHEMBL9560029 | 0.84 | CYSLTR2 (0.77) | CYSLTR2CYSLTR1 | |
| SCHEMBL9559806 | 0.83 | CYSLTR2 (0.78) | CYSLTR2CYSLTR1 | |
| SCHEMBL10448312 | 0.83 | CYSLTR2 (0.40) | CYSLTR2CYSLTR1 | |
| SCHEMBL9560087 | 0.82 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1BIDBCL2L1MCL1 | |
| SCHEMBL9560190 | 0.82 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1BIDBCL2L1MCL1 | |
| SCHEMBL9559989 | 0.82 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1BIDBCL2L1MCL1 | |
| SCHEMBL9559931 | 0.81 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1BIDBCL2L1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0202759-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-20 | — | — | EP | claimed |
| US-4874792-A | RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-10-17 | — | — | US | claimed |
| EP-0202759-A2 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1986-11-26 | — | — | EP | claimed |
| EP-0358240-B1 | INTERMEDIATES FOR THE PREPARATION OF LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-06-09 | — | — | EP | disclosed |
| US-5034537-A | Alpha-methyl-4-halobenzenemethanamine salts of acids for cardiovascular disorders, respiratory system disorders and antiallergens | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-23 | — | — | US | disclosed |
| US-4939279-A | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0202759-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-20 | — | — | EP | disclosed |
| EP-0358240-A2 | Intermediates for the preparation of leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4874792-A | RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-10-17 | — | — | US | disclosed |
| US-4820719-A | ANTIALLERGENS, ANTIINFLAMMATORY, ANTIISCHEMIC AND HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0202759-A2 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1986-11-26 | — | — | EP | disclosed |